Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Methylphenidate (MPH) is commonly prescribed in the treatment of Attention-Deficit/Hyperactivity Disorder or ADHD. Concerta and Metadate CD are once-daily formulations of MPH using different delivery mechanisms resulting in different pharmacokinetic profiles. A recent study (COMACS) showed that for near-milligram (mg) equivalent daily doses, Metadate CD provides greater symptom control in the morning (1.5 through 4.5 hours post-dose), while Concerta provides greater control in the early evening (12 hours post-dose). Non-inferential comparison of effects for different dose levels of the two formulations suggested that equivalent levels of morning symptom control could be obtained with lower daily doses of Metadate CD than Concerta; the situation being reversed in the evening. The current paper presents a secondary analysis that provides a statistical test of these observations. Method: The COMACS study was a multi-center, double-blind crossover study of Metadate CD, Concerta and placebo with each treatment administered for 1 week. Children were assigned on the basis of their pre-trial dosage to either high (Metadate CD 60 mg; Concerta 54 mg), medium (Metadate CD 40 mg; Concerta 36 mg) or low doses (Metadate CD 20 mg; Concerta 18 mg) of MPH, and attended a laboratory school on the 7th day for assessment at 7 sessions across the day. For the post-hoc comparisons across dose levels presented here, total SKAMP scores with the active treatments (adjusted for placebo response) were analyzed using an analysis of covariance, with a combined measure modeling placebo response across all time period as the covariate. Results: Symptom control from 1.5 through 6.0 hours post-dose was as good with lower doses of Metadate CD (20 and 40 mg) as with higher doses of Concerta (36 and 54 mg, respectively). Lower daily doses of Concerta (18 and 36 mg) and higher doses of Metadate CD (40 and 60 mg, respectively) gave equivalent control at 7.5 and 12 hours with Metadate CD giving better control from1.5 through 6.0 hours post-dose. Conclusions: Different delivery profiles of Metadate CD and Concerta can be exploited to limit total daily exposure to MPH while at the same targeting a specific, especially clinically significant, period of the day. These results need to be confirmed in a study in which children are randomly allocated to different dose levels of the two formulations and plasma MPH concentrations are assessed simultaneously.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Self-citationSwanson, J., Gupta, S., Lam, A., Shoulson, I., Lerner, M., Modi, N., Lindemulder, E., & Wigal, S. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.204 · Cited by 248
Self-citationSwanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., Kollins, S., Nguyen, A. S., DeCory, H. H., Hirshe Dirksen, S. J., et al. (2004) · Pediatrics · doi:10.1542/peds.113.3.e206 · Cited by 238 · cited 12×
“Assessments took place in the laboratory school on Days 7, 14, and 21 (for a detailed description of the laboratory classroom day see Swanson et al., 2004 [12]).”
BackgroundMethodInfluentialSelf-citationSwanson, J. M., & Volkow, N. D. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00433-8 · Cited by 173
Self-citationPelham, W. E., Sturges, J., Hoza, J., Schmidt, C., Bijlsma, J. J., Milich, R., & Moorer, S. (1987) · PEDIATRICS · doi:10.1542/peds.80.4.491 · Cited by 167
Cited by
Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., Danckaerts, M., Döpfner, M., Faraone, S. V., Rothenberger, A., et al. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0549-0 · Cited by 375
Self-citationMethylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Nutt, D. J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K., Morris, K. A., Santosh, P., Sonuga-Barke, E., Taylor, E., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073219 · Cited by 259
“…which can be precursors to dependency; in particular, from baseline data of COMACs (Swanson et al., 2004; Sonuga-Barke et al., 2005) and from the titration phase of the MTA (Galanter et al., 2003), in which possible rebound was seen that might be due to tolerance (Sonuga-Barke et al., 2004).”
BackgroundSelf-citationSonuga-Barke, E. J. S., Coghill, D., Wigal, T., DeBacker, M., & Swanson, J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0024 · Cited by 71
“A secondary analysis (Sonuga-Barke et al. 2004) found that when patients were compared across dosing strata, to approximately match their immediate release (IR) components, then the Equasym XL =Metadate CD (EQXL-MCD) advantage in the early part of the day over Concerta (CON) was minimized.”
Self-citationCornforth, C., Sonuga-Barke, E., & Coghill, D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791959827 · Cited by 41
“The relationship between the PK and pharmacodynamics (PD) of MPH is complex and inc ompletely understood; however recent studies have suggested that the main clinica l effects closely follow the predicted PK profiles [16, 17].”
BackgroundSelf-citation
Metadata
- Authors
- Sonuga-Barke, E. J., Swanson, J. M., Coghill, D., DeCory, H. H., & Hatch, S. J.
- Venue
- BMC Psychiatry
- Published
- 2004-09-30
- Volume
- 4
- Issue
- 1
- Pages
- 28-28
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W1586258382
- Cited by
- 48
- References
- 6
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data. https://app.cochat.ai/papers/10.1186/1471-244x-4-28
- The paper
- Sonuga-Barke, E. J., Swanson, J. M., Coghill, D., DeCory, H. H., & Hatch, S. J. (2004). Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry. https://doi.org/10.1186/1471-244x-4-28
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.